All In Biotech

Drug Trial Radar · NCT07697339

HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma

A Phase Ib/III Clinical Trial to Evaluate HDM2005 in Combination Therapy for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Aug 10, 2027

Study completion Dec 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/III, multicenter, open-label clinical study of HDM2005 in combination with rituximab and lenalidomide in adult patients with relapsed or refractory mantle cell lymphoma. Mantle cell lymphoma is a type of non-Hodgkin lymphoma. Some patients have disease that comes back after treatment or does not respond well to available treatments. This study is designed to evaluate whether adding HDM2005 to rituximab and lenalidomide may provide clinical benefit for patients with relapsed or refractory mantle cell lymphoma who have previously received an anti-CD20 antibody-containing regimen and at least one Bruton's tyrosine kinase inhibitor. The study includes two parts. In the Phase Ib part, participants will receive HDM2005 in combination with rituximab and lenalidomide. The main goals of this part are to evaluate the safety and tolerability of the combination, assess preliminary anti-tumor activity, and determine the recommended dose of HDM2005 for the Phase III part. In the Phase III part, eligible participants will be randomly assigned to receive either HDM2005 at the recommended Phase III dose in combination with rituximab and lenalidomide, or the investigator's choice of comparator treatment with rituximab plus lenalidomide or bendamustine plus rituximab. The main goals of the Phase III part are to compare the anti-tumor activity and clinical benefit of the HDM2005 combination with the comparator treatments. The main measures of efficacy include objective response rate and progression-free survival, assessed according to the 2014 Lugano response criteria. The study will also evaluate safety, pharmacokinetics, immunogenicity, overall survival, duration of response, and other measures of anti-tumor activity.

Conditions

  • Mantle Cell Lymphoma

Interventions

  • Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-LenDrug

    HDM2005 will be administered in combination with rituximab and lenalidomide.

  • Rituximab plus lenalidomideDrug

    Rituximab plus lenalidomide is used as part of the HDM2005 combination regimen and may also be selected as comparator treatment in the Phase III part.

  • Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-LenDrug

    HDM2005 will be administered in combination with rituximab and lenalidomide.

  • HDM2005 plus rituximab and lenalidomideDrug

    HDM2005 will be administered in combination with rituximab and lenalidomide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence and severity of adverse eventsTime frame: From the date of first dose until end of treatment, assessed up to 12 months.
  2. Phase Ib: Objective response rate assessed by investigatorTime frame: From the first dose of study treatment until disease progression, or other protocol re-specified reasesons, whichever occurs first, assessed up to 11 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.